Allergy Therapeutics plc (AGY) Given Buy Rating at Panmure Gordon
Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating reaffirmed by stock analysts at Panmure Gordon in a report issued on Monday. They currently have a GBX 53 ($0.69) price objective on the stock. Panmure Gordon’s price objective indicates a potential upside of 171.79% from the company’s current price.
AGY has been the subject of several other research reports. Stifel Nicolaus restated a “buy” rating and issued a GBX 72 ($0.94) target price on shares of Allergy Therapeutics plc in a report on Friday, July 8th. Numis Securities Ltd assumed coverage on shares of Allergy Therapeutics plc in a report on Wednesday, September 21st. They issued a “buy” rating and a GBX 37 ($0.48) target price for the company.
Shares of Allergy Therapeutics plc (LON:AGY) opened at 21.2749 on Monday. Allergy Therapeutics plc has a one year low of GBX 17.25 and a one year high of GBX 34.82. The stock’s market cap is GBX 125.34 million. The firm has a 50-day moving average of GBX 18.82 and a 200-day moving average of GBX 22.15.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/allergy-therapeutics-plc-agy-given-buy-rating-at-panmure-gordon.html
In related news, insider Nicolas Wykeman acquired 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 27th. The stock was bought at an average price of GBX 18 ($0.23) per share, for a total transaction of £27,000 ($35,243.44). Also, insider Peter Jensen acquired 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 29th. The shares were bought at an average price of GBX 19 ($0.25) per share, with a total value of £5,700 ($7,440.28).
Allergy Therapeutics plc Company Profile
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.